ABSI Absci Corp
Company Analysis
Latest News
🟢 Absci is trading 5.39% up today after detailing Phase 2 ABS-201 endometriosis trial
Absci is trading at $10.27, up 5.39%, after announcing preliminary details of its Phase 2 STORYLINE trial of AI-designed ABS-201 for endometriosis. - The...
Absci Advances AI-Designed Endometriosis Drug to Phase 2 Trial
Absci announced preliminary details for its Phase 2 STORYLINE™ clinical trial of ABS-201. The generative AI-designed antibody targets endometriosis. This...
🔴 Absci is trading 10.5% down today as Brent tops $100, Treasury yields near 5%
Absci is trading at $9.59 (-10.50%) as broader risk-off sentiment pressures equities, with Brent crude above $100 and Treasury yields approaching 5%. • The...
🔴 Absci is trading 5.5% down today as higher oil and Treasury yields pressure equities
Absci is trading 5.5% lower at $10.12, as broader market pressure from higher crude oil and Treasury yields weighs on equities. - The Nasdaq is down 1.11%. -...
🟢 Absci is trading 10.59% up today with no clear catalyst identified
Absci is trading 10.59% up now at $10.86, with no clear company-specific catalyst identified for September 22, 2026. - The latest notable item is an updated...
🟢 Absci is trading 6.67% up today with no clear catalyst identified
Absci is trading 6.67% up now at $10.47, but the catalyst remains unclear. - No new company-specific announcement dated September 22, 2026, was identified;...
🟢 Absci is trading 16.6% up today after encouraging ABS-201 safety data
Absci is trading at $9.38, up 16.60%, after interim Phase I/II data for ABS-201 showed no serious adverse events. - September 16 Morgan Stanley conference...
Absci's AI-Designed Hair-Loss Drug Clears a Safety Hurdle — But Can a Company Burning $100M a Year Survive Long Enough to Prove It Works?
Shares of Absci Corp jumped 9.8% to $8.83 after CEO Sean McClain presented updated safety results from the company's lead hair-loss drug at the Morgan Stanley...
🟢 Absci is trading 9.83% up today after encouraging interim ABS-201 Phase I/II results
Absci is trading 9.83% up now at $8.83 after presenting encouraging interim ABS-201 Phase I/II results. - No serious adverse events were reported among 32...
Absci reports safe hair loss drug results, targeting $25 billion market
Absci Corporation presented interim Phase I/II data for its hair-loss treatment, ABS-201, at the Morgan Stanley Global Healthcare Conference. The study...
🔴 Absci is trading 5.66% down today amid hotter-than-expected wholesale inflation
Absci is trading 5.66% down now at $8.16 after broad market weakness tied to hotter-than-expected wholesale inflation, elevated rate concerns, and renewed...
🔴 Absci is trading 5% down today with no clear company-specific catalyst
Absci is trading 5.20% down now at $8.38, with no clear company-specific catalyst identified for the September 2, 2026 decline. - The latest company...
🔴 Absci falls 5.5% — Biotech Sector Declines Amid Fed Rate Hike Fears
With Biotech (XBI) down 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Absci is trading 6.54% down today with no confirmed company-specific announcement
Absci is trading 6.54% down at $9.00 after no confirmed company-specific announcement was identified for August 26, 2026. - The latest major company update...
🟢 Absci is trading 7% up today on biotech-sector strength
Absci is trading at $9.46 (+7.07%) after opening-market strength on August 25, 2026, with the move primarily supported by biotechnology-sector momentum. • No...
🔴 Absci is trading 7.5% down today; no company-specific announcement confirmed
Absci is trading 7.5% down at $8.84, with no confirmed company-specific announcement identified for August 24, 2026. - The Nasdaq Composite is down 0.55% as...
🟢 Absci is trading 5.6% up today; immediate reason remains unclear
Absci is trading 5.6% up at $9.80, rebounding from its August 20 close of $9.28 after a volatile week, though no immediate reason has been identified. - No...
🔴 Absci falls 5.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Absci is trading 10.49% up today amid broad biotechnology rally
Absci is trading 10.49% up at $9.78 after a broad biotechnology rally on August 19, 2026. - No new company-specific announcement was identified on August...
🟢 Absci is trading 8.08% up today amid biotech-sector strength
Absci is trading 8.08% up at $9.58, with the move best explained by biotech-sector strength. - No new company-specific announcement was identified on August...